Karuna Therapeutics Q2 EPS $(2.75) Beats $(2.78) Estimate
Portfolio Pulse from sunil@benzinga.com
Karuna Therapeutics reported Q2 losses of $(2.75) per share, beating the analyst consensus estimate of $(2.78) by 1.08 percent. However, this is a 26.73 percent increase in losses compared to the same period last year.
August 04, 2023 | 12:50 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Karuna Therapeutics reported a smaller loss than expected in Q2, but the loss increased significantly compared to last year.
While Karuna Therapeutics beat the consensus estimate, the increase in losses compared to the same period last year could potentially concern investors. The impact on the stock price could be neutral in the short term as the positive and negative factors balance each other out.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100